SPG may be disappointingMaria Bartiromo, After the Bell, talked about SPG this morning on CNBC. SGP Near term caution on valuation. Stock is up 24% since 10/15. Rebetron prescriptions may be disappointing. Telling clients could see vulnerability, selling pressure, could have overhang going forward. Has not been involved in any merger deals, could be a negative.
For analysts views on SPG
https://www.netcognizance.com/Pharma.htm#Views_on_SGP